News | April 06, 2022
AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain
The new facility is scheduled to start operation in the first half of 2024
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Subscribe To Our Newsletter & Stay Updated
